{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=91&state=Texas",
    "query": {
      "state": "Texas",
      "city": "Houston",
      "page": 91
    },
    "page_size": 10
  },
  "pagination": {
    "page": 91,
    "page_size": 10,
    "total_count": 22541,
    "total_pages": 2255,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=92&state=Texas&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=90&state=Texas&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T04:10:01.607Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02431806",
      "title": "Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Levomilnacipran",
          "type": "DRUG"
        },
        {
          "name": "Fluoxetine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 552,
      "start_date": "2015-06-23",
      "completion_date": "2019-08-19",
      "has_results": true,
      "last_update_posted_date": "2020-09-07",
      "last_synced_at": "2026-11-19T04:10:01.607Z",
      "location_count": 48,
      "location_summary": "Dothan, Alabama • Tucson, Arizona • Anaheim, California + 40 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Imperial",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02431806"
    },
    {
      "nct_id": "NCT00003752",
      "title": "Bexarotene in Treating Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "bexarotene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ligand Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "1998-10",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2013-05-30",
      "last_synced_at": "2026-11-19T04:10:01.607Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003752"
    },
    {
      "nct_id": "NCT04842747",
      "title": "VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV Infection"
      ],
      "interventions": [
        {
          "name": "VERU-111",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veru Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 204,
      "start_date": "2021-05-18",
      "completion_date": "2022-07-06",
      "has_results": true,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-11-19T04:10:01.607Z",
      "location_count": 21,
      "location_summary": "Scottsdale, Arizona • Jonesboro, Arkansas • Chula Vista, California + 16 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04842747"
    },
    {
      "nct_id": "NCT03549338",
      "title": "Sym004 Versus Futuximab or Modotuximab in Patients With mCRC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer",
        "Colorectal Cancer Metastatic",
        "Carcinoma"
      ],
      "interventions": [
        {
          "name": "Sym004",
          "type": "DRUG"
        },
        {
          "name": "Futuximab",
          "type": "DRUG"
        },
        {
          "name": "Modotuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Symphogen A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2018-11-29",
      "completion_date": "2019-03-09",
      "has_results": true,
      "last_update_posted_date": "2020-09-28",
      "last_synced_at": "2026-11-19T04:10:01.607Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03549338"
    },
    {
      "nct_id": "NCT00360438",
      "title": "Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Tumor Lysis Syndrome"
      ],
      "interventions": [
        {
          "name": "Rasburicase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2006-07",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2012-08-01",
      "last_synced_at": "2026-11-19T04:10:01.607Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00360438"
    },
    {
      "nct_id": "NCT03291938",
      "title": "IACS-010759 in Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "Metastatic Malignant Solid Neoplasm",
        "Pancreatic Ductal Adenocarcinoma",
        "Progesterone Receptor Negative",
        "Prognostic Stage III Breast Cancer AJCC v8",
        "Prognostic Stage IIIA Breast Cancer AJCC v8",
        "Prognostic Stage IIIB Breast Cancer AJCC v8",
        "Prognostic Stage IIIC Breast Cancer AJCC v8",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Recurrent Lymphoma",
        "Refractory Lymphoma",
        "Stage II Pancreatic Cancer AJCC v8",
        "Stage IIA Pancreatic Cancer AJCC v8",
        "Stage IIB Pancreatic Cancer AJCC v8",
        "Stage III Pancreatic Cancer AJCC v8",
        "Stage IV Pancreatic Cancer AJCC v8",
        "Triple-Negative Breast Carcinoma",
        "Unresectable Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Oxidative Phosphorylation Inhibitor IACS-010759",
          "type": "DRUG"
        },
        {
          "name": "Pharmacodynamic Study",
          "type": "OTHER"
        },
        {
          "name": "Pharmacokinetic Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2017-11-13",
      "completion_date": "2020-11-23",
      "has_results": false,
      "last_update_posted_date": "2020-11-24",
      "last_synced_at": "2026-11-19T04:10:01.607Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03291938"
    },
    {
      "nct_id": "NCT02912949",
      "title": "A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumours Harboring NRG1 Fusion",
        "NSCLC Harboring NRG1 Fusion",
        "Pancreatic Cancer Harboring NRG1 Fusion",
        "NRG1 Fusion"
      ],
      "interventions": [
        {
          "name": "zenocutuzumab (MCLA-128)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Partner Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2015-01",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-11-19T04:10:01.607Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Cerritos, California • Irvine, California + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02912949"
    },
    {
      "nct_id": "NCT00268957",
      "title": "Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Diseases",
        "Chronic Renal Insufficiency",
        "End-Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Sevelamer carbonate (Renvela®)",
          "type": "DRUG"
        },
        {
          "name": "Sevelamer hydrochloride (Renagel®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 217,
      "start_date": "2006-01",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2014-03-19",
      "last_synced_at": "2026-11-19T04:10:01.607Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Gadsden, Alabama • Mission Hills, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gadsden",
          "state": "Alabama"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        },
        {
          "city": "Crystal River",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00268957"
    },
    {
      "nct_id": "NCT02528357",
      "title": "GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "GSK3174998",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 141,
      "start_date": "2015-09-11",
      "completion_date": "2020-04-29",
      "has_results": true,
      "last_update_posted_date": "2021-05-18",
      "last_synced_at": "2026-11-19T04:10:01.607Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02528357"
    },
    {
      "nct_id": "NCT00486265",
      "title": "Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "AZD4877",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2007-07",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2010-12-21",
      "last_synced_at": "2026-11-19T04:10:01.607Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00486265"
    }
  ]
}